Next Article in Journal
Wild Birds in Live Birds Markets: Potential Reservoirs of Enzootic Avian Influenza Viruses and Antimicrobial Resistant Enterobacteriaceae in Northern Egypt
Next Article in Special Issue
Lassa Fever: Viral Replication, Disease Pathogenesis, and Host Immune Modulations
Previous Article in Journal
Lineage, Antimicrobial Resistance and Virulence of Citrobacter spp
Previous Article in Special Issue
A Single Dose of Modified Vaccinia Ankara Expressing Lassa Virus-like Particles Protects Mice from Lethal Intra-cerebral Virus Challenge
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Pathogens
Volume 9
Issue 3
10.3390/pathogens9030197
pathogens-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles thumb_up
...
Endorse textsms
...
Comment
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Review

Animal Models of Lassa Fever

by
Rachel A. Sattler
1,
Slobodan Paessler
1,
Hinh Ly
2 and
Cheng Huang
1,*
1
Department of Pathology, University of Texas Medical Branch, 301 University Blvd., Galveston, TX 77555-0609, USA
2
Department of Veterinary Biomedical Sciences, University of Minnesota, Twin Cities, 1988 Fitch Ave., 295H Animal Science Veterinary Medicine Bldg., Saint Paul, MN 55108, USA
*
Author to whom correspondence should be addressed.
Pathogens 2020, 9(3), 197; https://doi.org/10.3390/pathogens9030197
Submission received: 27 January 2020 / Revised: 26 February 2020 / Accepted: 27 February 2020 / Published: 6 March 2020
(This article belongs to the Special Issue Lassa Fever: Viral Replication, Disease Pathogenesis, and Host Immune Modulations)
Versions Notes

Abstract

:
Lassa virus (LASV), the causative agent of Lassa fever, is estimated to be responsible for up to 300,000 new infections and 5000 deaths each year across Western Africa. The most recent 2018 and 2019 Nigerian outbreaks featured alarmingly high fatality rates of up to 25.4%. In addition to the severity and high fatality of the disease, a significant population of survivors suffer from long-term sequelae, such as sensorineural hearing loss, resulting in a huge socioeconomic burden in endemic regions. There are no Food and Drug Administration (FDA)-approved vaccines, and therapeutics remain extremely limited for Lassa fever. Development of countermeasures depends on relevant animal models that can develop a disease strongly mimicking the pathogenic features of Lassa fever in humans. The objective of this review is to evaluate the currently available animal models for LASV infection with an emphasis on their pathogenic and histologic characteristics as well as recent advances in the development of a suitable rodent model. This information may facilitate the development of an improved animal model for understanding disease pathogenesis of Lassa fever and for vaccine or antiviral testing.

1. Introduction

Lassa virus (LASV) is the causative agent of Lassa fever (LF). The virus was first isolated from two missionary nurses who died from LF in Nigeria in 1969 [1,2,3]. A third nurse was infected and brought to the United States; her plasma was used to treat a fourth patient who was exposed by handling infected blood samples [1]. LASV is a mammarenavirus from the Arenaviridae family and has a single-stranded, negative-sense, bisegmented RNA genome. LASV is endemic throughout Western Africa, especially in Nigeria, Liberia, Guinea, and Sierra Leone, where it is transmitted by the Natal mastomys (Mastomys natalensis) rodent, although recent work suggests viral presence in the reddish-white mastomys (Mastomys erythroleucus) and the “African wood mouse” (Hylomyscus pamfi) rodents as well [2,4]. LASV isolates of different geographic and host origins are highly diverse in genomic sequences and phylogenetically classified into up to seven lineages, with each lineage predominately localized in specific countries (refer to Table 1 for the LASV isolates covered in this review) [5,6,7,8,9]. A recent deep sequencing analysis revealed that the sequence variations could be as high as 25% and 32% in the viral genomic small (S) and large (L) segments, respectively, among different strains [5]. LASV causes zoonotic infections in humans, typically through the ingestion of contaminated food and/or water or inhalation of tainted aerosols from infected rodents; person-to-person transmission occurs via contact with bodily fluids [2]. Estimates from the Centers for Disease Control and Prevention (CDC) place the number of new LASV infections each year as high as 300,000 with around 5000 deaths from LF [2,10]. The average case fatality rate is approximately 1%, which can dramatically elevate to 15–20% for hospitalized cases [2]. However, a more recent report indicated only 633 confirmed cases and 171 deaths in Nigeria in 2018, with a 27% case fatality rate [11]. In the recent 2018–2019 Nigerian LF outbreaks, approximately 25% of patients died from the infection [12,13,14]. Therefore, it is necessary to re-evaluate the annual incidence of LASV infections and deaths.
There are no FDA-approved vaccines against LASV. Current clinical treatments are limited to an off-label use of ribavirin [2,14]. However, ribavirin treatment is expensive and only effective if administered within the first six days after the onset of symptoms [15]. When considering the high rate of misdiagnosis of LF for other endemic infections, such as typhoid or falciparum malaria [1,2,16,17], this time frame for effective LF treatment is extremely challenging [16]. Moreover, ribavirin has a high rate of side effects that often require further medical intervention, such as hemolysis [15]. Development of countermeasures against LF requires relevant animal models that can recapitulate disease and pathogenic features of LF in humans. The objective of this review is to survey the current Lassa fever animal models, including their pathologic and histologic characteristics as well as new advances in small rodent models, in order to inform the development of new animal models.

2. Lassa Fever Symptoms and Pathogenesis

LF symptoms typically appear 1–3 weeks post-infection [2]. Eighty percent of cases are asymptomatic or present with mild, non-specific febrile symptoms such as fever, sore throat, headache, and general malaise, that may be misdiagnosed as typhoid, malaria, or appendicitis [1,2,16,17]. The other 20% of cases progress to much more severe symptomology [2]. These clinical manifestations include diarrhea, hemorrhage, disorientation, respiratory distress, abdominal pain, vomiting, facial edema, and severe pharyngitis [1,2]. Neurological signs such as hearing loss, encephalitis, and tremors also occur [2]. Of note, this hearing loss manifests as sudden-onset sensorineural hearing loss (SNHL) in approximately one-third of patients and is irreversible in two-thirds of those cases [10,18,19]. Infections during pregnancy have a greater risk of death as well as spontaneous abortion [20]. Death will typically occur due to multiorgan failure approximately two weeks post-onset of symptoms [2]. The long-term sequelae, such as SNHL, are generating a huge socioeconomic burden across Western Africa, where stigmatization and isolation lead to increased rates of depression and unemployment [21]. Aid programs in Nigeria alone can cost upwards of $43 million each year [18].
Clinical laboratory findings include thrombocytopenia, leucopenia with lymphopenia, elevated blood urea and proteinuria [22]. The aspartate aminotransferase (AST), alanine aminotransferase (ALT), amylase, and creatine phosphokinase (CPK) concentrations are also elevated in patient’s serum [17], often with a higher AST level than ALT level, suggesting that the transaminases in serum are not solely derived from damaged liver, but may also be from other tissues [23]. High viral titers are measured in the spleen, lung, liver, kidney, heart, mammary gland, and placenta [17]. The level of viremia has been correlated with the severity of disease outcome.
Current knowledge on the pathology of Lassa fever is still limited due to civil unrest and social taboos and customs when dealing with the deceased in endemic areas [22]. Available pathologic analysis of clinical cases indicates lesions in the spleen, liver, and adrenal glands [17]. Histologic analysis of the liver indicates significant eosinophilic necrosis and parenchymal cell necrosis with an infiltration of eosinophils in the sinusoids [1,17,24]. Spleen samples indicate a presence of eosinophilic necrosis, lymphoid depletion, atrophied white pulp, and fibrin deposits with an infiltration of lymphocytes and mononuclear cells [1,17,24]. Adrenal gland samples indicate multifocal adrenocortical cellular necrosis, often associated with inflammation [17]. Less frequent findings include petechiae of the gastrointestinal tract, interstitial nephritis, renal tubular injury, lymph node sinus histiocytosis, mild interstitial pneumonia, renal edema and hemorrhage, as well as mild interstitial mononuclear myocarditis [1,17,24]. No alterations are detected in placental, mammary, uterine, ovarian, pancreatic, central nervous system (CNS), or brain samples [17]. These observations were made from a study performed in 1982. Our knowledge on pathology of LF in humans still lack. Studies with non-human primates have provided valuable information regarding the pathogenesis of LASV infection. As there is a limitation in study with non-human primates (NHPs), a small animal model that can resemble pathological changes in LF patients is desired.

3. Murine Models

3.1. Natal Mastomys (Mastomys Natalensis) Mice

Natal mastomys mice are the natural host of LASV. The exact subspecies that acts as a LASV reservoir remains unclear, due to multiple subspecies coexisting in endemic regions and their high genetic diversity [25,26]. There are very few studies on laboratory infections of Natal mastomys due to lack of laboratory clone of these mice. One early study reported that LASV caused a chronic asymptomatic infection despite the high virus titers detected in organs at 74 days post-infection (dpi) [25] (Table 2). Affected tissues included the lung, spleen, liver, kidney, brain, bladder, and lymph nodes [25]. Virus was also detected in the blood and urine. As the Natal mastomys mice did not develop LF signs, its use in viral pathogenesis or vaccine studies is limited. However, this model may prove useful for basic transmission studies as well as studies developing methods for limiting transmission of the virus between rodent populations or from rodents to humans.

3.2. IFNAR-/- Mice

Immune-competent laboratory mice are generally resistant to LASV infection [27,28,29,30]. Interferons play important roles in regulating host innate and adaptive immune responses against infections. LASV infection of the 129Sv mice lacking the receptor for interferon α and β (IFNAR-/-) results in a non-lethal acute infection accompanied with persistent viremia [27,28,29,30] (Table 2). Infected mice lose approximately 15% body weight but did not develop febrile or neurological signs [26,29]. Other disease signs included ruffled fur and hypoactivity occurring by 11 dpi [28,30]. Peak viremia occurred approximately 8 dpi. The lung, liver, and spleen had the highest viral loads, and virus was also present in the brain, kidney, and heart at much lower titers [27]. Similar pathological changes and disease signs were found in the animals upon infection with a variety of LASV strains, including the Josiah, AV, BA366, and Nig04-10 strains isolated from endemic countries, Sierra Leone, Côte d’Ivoire, Guinea, and Nigeria, respectively [27,28].
A chimeric IFNAR-/-B6 lethal mouse model had been established, in which the IFNAR-/- mice were irradiated and transplanted with bone marrow progenitor cells from wild type C57BL/6 mice. These IFNAR-/-B6 chimeric mice uniformly succumbed to infections with a variety of LASV strains within 10 days [29,31]. LASV strains tested include Ba366, AV, Ba289, Nig04-10, and Nig-CSF, all of which were 100% lethal using 1000 focus-forming units (FFU) [29]. These mice presented with liver damage, vascular leakage, and systemic viral dissemination [29]. Virus titers were detected in the liver, lung, spleen, kidney, heart, brain, and blood [29,31]. Animals also presented with weight loss and hypothermia [31]. Moreover, this model featured an elevated AST/ALT ratio, as well as FAS and FAS-L [29,31] similarly observed in LF patients. Pathological findings included an infiltration of inflammatory leukocytes in the kidney, infiltration of granulocytes and T cell lymphocytes in the liver, and an increased presence of CD8+ T cells in both the spleen and lungs [29]. Lung and liver samples both presented with indications of significant vascular leakage as well as edema [29]. Interestingly, IFNAR-/-B6 mice with a depletion of CD8+ T cells exhibited significantly increased survival rate (87.5%) despite persistent viremia [29]. This depletion also reduced the FAS and FAS-L concentrations, as well as the vascular leakage in the liver and lung [29]. This model implicates the role of T cells in the pathogenesis of LF. IFNAR-/- mice are less susceptible to disease probably as a result of lacking IFN receptors that are critical to stimulate a T cell response.

3.3. IFNαβ/γR-/- Mice

The 129Sv mice lacking interferon α, β and γ receptors (IFNαβ/γR-/-) did not develop clinical signs of disease upon LASV infection apart from a minor and transient weight loss [30] (Table 2). Neither did this model develop sudden onset sensorineural hearing loss when infected with either the LF2384 or LF2350 clinical isolates from a fatal and a non-fatal case respectively, from the 2012 Sierra Leone outbreak [8]. These two clinical isolates have been passaged only once in Vero cells. The animals presented with less severe disease upon infection with the Josiah strain as IFNAR-/- mice [30]. Virus was present in the serum, spleen, lung, liver, brain, and kidney, but was cleared by 25 dpi [30]. Tissue samples featured similar findings to the LASV-infected IFNAR-/- model in the brain and lung, but to significantly lesser extents [30]. Liver samples presented with mononuclear cell infiltration, although inflammation was rarely observed [30]. In the spleen, only the red pulp was affected; the kidneys showed mild, regional nephritis [30].

3.4. STAT1-/- Mice

Signal transducer and activator of transcription 1 (STAT1) is a transcription factor that is activated in response to IFN α, β, γ and IL-6. The 129Sv mice lacking STAT1 (STAT1-/-) were not only highly susceptible to LASV infection, including clinical isolates, but also presented with a lethal disease with clinically relevant manifestations, such as SNHL [8,28]. Thus, the STAT1-/- mouse model is promising for vaccine and therapeutic testing. Mice intraperitoneally infected with 104 plaque forming units (PFUs) of the Josiah strain of LASV lost ~18% of their body weight between 4 and 6 dpi, and either died or met humane endpoint criteria by 7 dpi [28]. This model also matched the differential clinical outcome of the patients from whom the viruses were isolated, with LF2384 infections being lethal and LF2350 infections non-lethal in these mice. Intraperitoneal (IP) injection with 105 PFU of the LF2384 or the LF2350 isolates led to 80% and 10–50% lethality, respectively [8]. Infection with 104 PFU of these viruses resulted in 80% lethality for the fatal isolate and 0% lethality for the non-fatal isolate [8]. LF2384 also caused fever and other signs of disease by 4–5 dpi, and death approximately 7 dpi [28]. Other signs of disease included weight loss, hypothermia, hunched posture, reduced activity, and ruffled fur [8]. In one study, fever was not noted, although the possibility that fever transiently occurred before turning into hypothermia was raised [8,28]. Virus was disseminated to the brain, liver, spleen, lung, kidney, and heart by 3 dpi with titers steadily increasing to their peak at 7 dpi [8,28]. Viremia appeared by 3 dpi and remained at high titers until death [28]. Increased ALT concentrations and decreased albumin, WBC, and monocyte counts were noted as early as 3 dpi; a moderate decrease in platelet counts was also observed [28]. Histologic analysis of the spleen indicated lesions with eosinophil accumulation in the red pulp, primarily focused around the periarteriolar lymphocytic sheaths as well as apoptotic and necrotic cells [28]. Samples also demonstrated significant fibrin deposits and an infiltration of macrophages filled with apoptotic nuclei [28]. Analysis of the liver indicated lesions with microvesicular steatosis and apoptosis in the hepatic sinusoids [28]. Of note, IFN signaling is not completely disrupted in this STAT1-/- mouse model as that in IFNαβ/γR-/- mice. A partial knockout of STAT1 gene leads to expression of a truncated form of STAT1, which may still be able to mediate a minimal T cell response. As T cells may contribute to LF pathogenesis, the difference in IFN signaling may explain why the STAT1-/- mice are more susceptible to disease than IFNαβ/γR-/- mice [29].
Additionally, the STAT1-/- model is the only available small animal model for SNHL [8]. Both LF2384 and LF2350 clinical isolates from the 2012 Sierra Leone outbreak caused deafness in survivors [8]. Infection with 105 PFU of virus caused permanent hearing loss in all survivors. With a lower dose of virus (104 PFU), hearing loss was present in only 20% of survivors. Histologic examination identified severe damage to the inner ear with significantly fewer outer hair cells; inner hair cells remained intact [8]. Auditory nerves in mice with hearing loss were also damaged, while the nearby facial nerves remained intact. There was significant vacuolization of the spiral ganglion, thinning of the stria vascularis, distention of Reissner’s membrane, and an infiltration of blood cells in the scala tympani. Viral antigen was present in vascular-rich regions, where there was also a remarkable infiltration of CD3+ lymphocytes, indicating an immunopathologic mechanism underlying to the hearing loss [8].

3.5. CBA Mice

Intracranial infection of inbred CBA mice with the pathogenic Josiah strain of LASV resulted in disease manifestation, although it was unclear whether the animals were immunocompromised [32]. Infected CBA mice presented with scruffy fur, seizures, weight loss, immobility, severe decubitus paralysis, and death [32]. This route of inoculation allowed for onset of signs of disease between 5 and 7 dpi with 70–100% lethality within 7–12 days [32].

3.6. HHD Mice

C57BL/6 mice expressing a human/mouse chimeric HLA-A2.1 instead of the normal MHC class I gene products (humanized HHD mouse model) has recently been established as a novel model for LASV infection [33]. The HHD mouse was most susceptible to infection with the Ba366 strain and featured ~22% lethality and rapid deteriorating post-onset of signs of disease [33]. When infected with 106 PFU of the Ba366 strain, HHD mice began to show ruffled fur and lethargy, as well as elevated concentrations of serum AST, approximately 7–12 dpi [33]. High viral titers were observed in liver, lung, and spleen, whereas lower titers were seen in the kidney [33]. Histology examination indicated severe pneumonitis with signs of pleural effusion, thickening of the interlobular septum, and collapsed alveolar lumen with infiltration of monocytes and macrophages [33]. The liver contained altered cellular distribution, orientation, and shape of its monocytes and macrophages. The spleens also featured disruption of the white and red pulp regions, while monocytes and macrophages were found throughout with scarce T cells.
Depletion of CD4+ T cells, CD8+ T cells, or both resulted in substantial differences in disease manifestations in this model [33]. After infection, the serum AST concentrations remained normal in HHD mice lacking both CD4+ and CD8+ T cells, while the AST concentrations elevated in HHD mice. Additionally, depletion of either CD4+ T cells or CD8+ T cells resulted in partial elevation in AST concentrations [33]. In all groups, similarly high titers of viremia were developed, suggesting T cells had no substantial influence on viremia. C57BL6 mice lacking only CD4+ T cells were able to clear the viral infection, while those lacking only the CD8+ cells featured persistent viremia [33]. MHC-I-/- mice lacking CD8+ T cells confirmed these findings, presenting with no clinical manifestations of disease after infection, despite the high viremia [33]. CD4+ and CD8+ T cell-depleted mice did not demonstrate any significant histological changes in the lung and spleen after infection and also featured limited signs of disease, emphasizing the role of T cells in LASV pathogenesis [33].
In summary, immune-competent laboratory mice are generally resistant to LASV infection, and therefore are not suitable for modeling the severe and fatal LF diseases in humans. Immune-incompetent mice are susceptible to LASV infection but generally develop mild diseases and survive the infection (see Table 2). The chimeric IFNAR-/-B6 mice are susceptible to lethal LASV infection but require irradiation of the mice and transplantation with bone marrow progenitor cells from wild type C57BL/6 mice. Recently, progress has been made using the STAT1-/- mice, which recapitulate the pathogenic potency of different LASV isolates and some LF disease signs including hearing loss. This STAT1-/- mouse model may be useful as a small rodent model for vaccine and therapeutic testing.

4. Guinea Pig Models

4.1. Strain 13 Guinea Pigs

Inbred Strain 13 domesticated guinea pigs have been used as a lethal LF rodent model for studying pathogenesis as well as antiviral, vaccine, and immunotherapy candidates. Unlike their Hartley outbred counterpart, this model does not require virus adaptation [34,35] (Table 3). However, Inbred Strain 13 guinea pigs are not readily available, limiting their use as a LF animal model. In this model at least 90% animals died when infected with at least 2 PFU of LASV (Josiah) [34,36,37]. The clinical isolate NJ2015, from a non-fatal infection, was also non-lethal in Strain 13 guinea pigs [36]. Guinea pigs infected with the Pinneo strain had a 100% survival rate, developing only a mild to moderate disease featuring 5–10% weight loss and lethargy approximately 10 dpi; all animals recovered by 22 dpi [38]. The Z-132 strain was 100% lethal and mimicked a Josiah infection, while the Soromba-R strain was 0–57% lethal with a very mild disease [38,39]. Survivors did not exhibit seroconversion and were susceptible to back challenge [34]. Neutralizing antibodies were not produced [37]. Signs of disease included weight loss, fever, ruffled fur, hunched posture, altered mentation, and conjunctivitis [34,35,36]. Guinea pigs typically became moribund between 10 and 15 dpi [37]. A persistent and high level viremia developed rapidly, typically approximately 5–6 dpi, and peaked at approximately 10 dpi. The highest viral load was identified in the lung, followed by the spleen, pancreas, lymph nodes, adrenal glands, kidneys, salivary glands, liver, and heart [34,35,39]. Histological findings included the presence of viral antigen typically associated with hepatitis, hepatic cell death, hair follicle epithelium cell death, and adrenal cortical necrosis [35]. Laryngitis and heterophilic tracheitis were noted in guinea pigs exposed via aerosol [35]. Interstitial pneumonia was found in all moribund animals with an increase in mononuclear cells, especially macrophages, surrounding the blood vessels and airways [34,35,37,39]. Edema and hemorrhage were also noted in the lungs with an expansion of the alveolar septae [35,39]. Liver samples exhibited a mild to moderate inflammation in portal and sinusoidal regions, vacuolar degeneration, and necrosis [35,37,39]. Half of the guinea pigs developed acute necrotizing nephritis and mild myocarditis or mild to moderate endocarditis and pancarditis [34,35,37]. It is important to note that this damage to the heart is not seen in clinical cases [25]. Adrenal glands featured minimal damage, although they were infected [34,35]. Further analysis of the spleen identified mild heterophilic splenitis [35,39]. The red pulp featured perifollicular to diffuse mononuclear cell proliferation [35]. Most infected guinea pigs developed petechial rashes approximately 12 dpi [35]. Lymphocytolysis and lymphoid depletion was noted in the white pulp of the spleen, thymus, and lymph nodes [35,37]. The pancreas featured acinar cell atrophy as well as other architectural changes [35]. Viral antigen was present in the reproductive tissues of both male and female infected guinea pigs, with males also featuring mild epididymitis [35]. Serum analysis indicated elevated ALT and heterophil concentrations with a transient decrease in platelets and a decrease in blood lymphocytes [35].
Strain 13 guinea pigs presented with conjunctivitis upon LASV infection [36]. Clinically, LASV infections cause conjunctival edema and conjunctivitis in acute infections and transient blindness in survivors. No other animal models have been extensively studied for this aspect of disease, although viral titers have been identified in the aqueous humor of the eye of infected rhesus monkeys [36,44]. The lethal Josiah strain and the non-lethal NJ2015 clinical isolate both induced red and swollen conjunctiva with associated ocular discharge in the animals [36]. Viral antigen was detected in the eyes of all infected guinea pigs achieving humane euthanasia criteria, while none was detected in those of survivors [36]. Survivors presented with minimal to mild lymphocytic inflammation; lethal infections all presented with mild to moderate inflammation [36].

4.2. Hartley Guinea Pigs

Outbred Hartley domesticated guinea pigs are commercially available and susceptible to infection with the widely used Josiah strain of LASV (Table 3). However, the Josiah strain caused lethal infection in only 30–67% of animals regardless of the infection dose. Survivors seroconverted and were not susceptible to back challenge [34]. To achieve uniform lethality, the Josiah strain must be adapted in guinea pigs through serial passage [25,34,35,40,41]. Guinea pigs infected with the guinea pig-adapted LASV (GPA-LASV) developed a fever approximately 6–9 dpi as well as respiratory distress and hypothermia [41,42]. Weight loss was rapid and variable, ranging from 8% to over 20%, which is typical humane euthanasia criteria [40,41,42]. Other clinical manifestations included an unstable gait, a noticeable lack of grooming with associated rough/ruffled fur, delayed responsiveness/lethargy, recumbency, and a reddening of the footpads and ears [40,41]. Death occurred by an average of 15 dpi [41]. Viral titers were observed in the serum, spleen, liver, and lung [41,42]. Histologic analysis of the liver indicated lymphohistiocytic hepatitis and hepatocellular degeneration [41]. Spleen samples contained sinus histiocytosis and lung samples featured interstitial pneumonia [41]. The GPA-LASV/Hartley guinea pig model has been often used in development of antivirals and vaccine against LF [40,41,42].
Recently, new advances have been made in the development of the outbred LASV-infected Hartley guinea pig model by using the LF2384 clinical isolate. Uniform lethality could be achieved in outbred Hartley guinea pigs infected by the LF2384 clinical isolate without species-specific adaptation, at a dose as low as 100 PFU [45]. LF2384-infected guinea pigs presented with signs of disease such as fever, hypothermia before death, as well as weight loss by 10 dpi, scruffy coats by 12 dpi, and loss of appetite as well as lethargy by 13 dpi [45]. Neurological disease signs were not observed in this model [45]. Viral loads were detected in the liver, kidney, spleen, lung, and brain, but were not detectable in survivors of a low dose infection [45]. Guinea pigs succumbing to disease presented with thrombocytopenia, neutropenia, and lymphopenia [45]. Gross pathology indicated small spleens [45]. While this model requires further characterization, the advantages of this new LF model include the use of clinical isolates directly from patients without adaptation and the commercial availability of the animals. Additionally, the outbred background may allow for mimicking infections in humans with diverse genetic backgrounds. The newly developed LF2384 LASV/Hartley guinea pig model will be useful for vaccine and therapeutic development, which is demonstrated in a recent study showing that immunization with an adenovector-based LASV vaccine candidate efficaciously protected animals from lethal LASV infection [43].

5. Non-Human Primate Models

5.1. Squirrel Monkey Model

Squirrel monkeys (Saimiri sciureus) infected with the Bah strain of LASV developed variable disease. One out of four animals became moribund [46] (Table 4). These primates develop depression, tremors, drooling, anorexia, lassitude, and polydipsia as signs of disease. Serologic analysis indicated persistent viremia with no antibody development at 28 dpi [46]. High viral titers were detected primarily in the liver, kidney, and lymph nodes, while lower virus loads were found in the spleen, brain, liver, kidneys, adrenal gland, urine and heart [25,46]. The presence of the virus was associated with significant tissue necrosis [25]. Spleen and lymph node samples featured necrosis in the germinal centers; spleen samples and adrenal glands also contain regions of focal hemorrhage [46]. While the liver suffered from hepatitis with fatty metamorphosis and an infiltration of leukocytes and mononuclear cells, hepatocytic regeneration was noted [46]. Renal tubular necrosis and regeneration was present in the kidney, while heart samples featured severe myocarditis with vacuolar degeneration and necrosis [46]. Some animals developed neuropathology with chronic inflammation of the meninges, a significant infiltration of mononuclear cells and lymphocytes into the pancreas with acute arteritis, or minor pathologic changes in the adrenal gland, prostate, and bone marrow [46].

5.2. Marmoset Model

The common marmoset (Callithrix jacchus) has been identified as a good model for Lassa fever (Table 4). Primates infected with the Josiah strain of LASV develop a systemic disease featuring low fever and rapid weight loss [47]. These monkeys also exhibited behavioral changes, such as depression and anorexia, as well as reduced stool production [47]. Severe morbidity occurred between 15 and 20 dpi [47]. Serum analysis indicated an elevation in AST, ALT, and alkaline phosphatase concentrations as well as a decrease in albumin and platelet concentrations [47]. High viral titers were observed in the liver, spleen, and lymph nodes [47]. Livers were enlarged with pale patches. Histologic analysis indicated multifocal hepatic necrosis with mild inflammation [47]. Spleens were also enlarged with mild to moderate lymphoid depletion [47]. Likewise, lymph nodes were enlarged with lymphocyte necrosis and an infiltration of inflammatory cells [47]. Kidneys were pale with interstitial nephritis [47]. Lung samples featured hemorrhage present in most lobes with mild to moderate multifocal interstitial pneumonitis, septal thickening, and multifocal edema [47]. These samples also had increased infiltration of lymphocytes and macrophages [47]. The adrenal cortex also featured mild to moderate inflammation and multifocal necrosis [47].

5.3. Rhesus Monkey (Rhesus Macaque) Model

Rhesus monkeys (Rhesus macaques) infected with the Josiah strain of LASV develop severe disease with prolonged viremia [44]. Succumbed animals developed disease signs by 7 dpi, including severe petechial rash, hiccups, lethargy, aphagia, huddled posture, constipation, conjunctivitis, anorexia, weight loss, decreased water intake/dehydration, facial and periorbital edema, bleeding from the gums and nares, cough, and a slight fever [44,48,49,54,55]. Fever persisted until death or a sudden hypothermia happened just before death approximately 10–14 dpi [44,49,54,55]. Subcutaneous inoculation with 106.1 PFU of Josiah strain of LASV proved to be lethal in 60% of the animals [47]. Serologic analysis indicated antibody production by 10–12 dpi, although this was not correlated with viral clearance and animal recovery [44,49]. Elevated AST, ALT, and blood urea nitrogen (BUN) with a transient and moderate leukopenia was also noted [49,54,55]. Hematocrit, hemoglobin, fibronectin, and red blood cell counts decreased; platelet counts trended toward a decrease, although remained within the normal range [54,55]. Viremia appeared typically by 4–5 dpi with titers over 104 PFU/mL in lethally infected monkeys, significantly higher than those in survivors [49,54,55]. Viral loads were found in every organ tested including the adrenal glands, liver, lung, pancreas, brain, bone marrow, kidney, lymph nodes, spleen, muscle, heart, thymus, testis, salivary gland, urine, CSF, and intestines [44,49,55]. The highest titers were in the liver, spleen, and adrenal glands [55].
Gross pathological analysis indicated scattered petechial and visceral hemorrhage along with the presence of mild to moderate pleural effusions [44,48]. Liver and adrenal gland tissues presented with necrosis, with markers of regeneration of hepatocytes and a slight infiltration of inflammatory cells [44,48,49,55]. Interstitial pneumonia with edema, thickened alveolar septae, and pulmonary arteritis were present in the lung [44,48,49,55]. Spleen samples indicated lymphocytopenia and presence of viral antigens only in the red pulp [48,49]. Infected primates also developed mild to moderate interstitial and perivascular myocarditis and pericardial edema. Severe meningoencephalitis with significant perivascular cuffing was noted, albeit rarely [44,48]. Infiltration of erythrocytes and macrophages was noted in the small intestine. Lesions and a multifocal cortical interstitial mononuclear infiltrate were noted in the kidney [48,55]. Seventy-eight percent of infected primates developed lesions in the CNS with mild lymphocytic cuffing of the vessels of the brain, spinal cord, and meninges [48]. Twenty percent of primates suffered lymphocytic infiltration of the spiral ganglia; mild choriodoretinitis was also noted [48]. The arterial lesions, vasculitis, meningoencephalomyelitis and skeletal myositis observed in this monkey model were rarely, if at all, noted in human LF cases [44].

5.4. Cynomolgus Macaque Model

Josiah- or Z-132-infected “crab-eating” (cynomolgus) macaques developed a severe hemorrhagic disease with up to 100% of primates becoming moribund or dying between 11 and 18 dpi [38,39,50,51,52,53,56]. A study with the Soromba-R strain found two of three animals died (66% lethality) after infection and a prolonged time to euthanasia [39]. Infection with the Liberian LASV Z-132 strain was 100% lethal by 18 dpi [35]. Infection with 103 FFU AV strain featured only 67% lethality. All animals survived infection with 107 FFU of the AV strain, probably due to a high concentration of defective interfering (DI) viral particles in the higher dose [57]. Clinical signs, such as fever, weight loss, lethargy, dull appearance, reluctance to move/hypoactivity, anorexia, rashes, facial edema, hunched posture, ruffled fur, piloerection, bleeding from puncture sites, dehydration, epistaxis, acute respiratory syndrome, and mild to moderate depression appeared approximately 5-7 dpi, but might begin as early as 3 dpi [38,39,50,51,52,56,57,58]. Fever spiked between 7 and 10 dpi [39]. Viremia might start as early as 3–4 dpi, but was usually detectable 6–10 dpi, peaked 12–14 dpi, and continued to maintain high titers (up to 107 PFU/mL) until death or euthanasia [39,50,51,53,56,58]. Onset of fever was associated with detectable viremia. Survivors typically had a lower virus titer and cleared the virus by 28 dpi [50,57]. Survivors suffered neurological disorders such as tremors, reduced appetite, ataxia, convulsions/seizures, and unilateral or bilateral deafness [50,52,56,58]. Sixty-seven percent of the survivors developed hearing loss, which was thought to be driven by an immune-associated systemic vasculitis [50,56]. This hearing loss was present in all survivors of one study, presenting as unilateral or bilateral hearing loss [56].
Serologic analysis indicated elevated concentrations of AST, ALT, alkaline phosphatase (ALP), gamma-glutamyltransferase (GGT), total bilirubin (TBIL), and BUN as well as decreased concentrations of albumin, total protein, and amylase [38,39,50,51,58]. Transient lymphopenia, monocytopenia, neutropenia, and eosinopenia were also noticed at 4–10 dpi [38,39,50,51,58]. Platelet concentrations typically tended to decrease but remained within normal ranges, along with reduced hemoglobin, hematocrit, and creatinine concentrations [39,50,51,58]. The autoimmune markers C-reactive protein, antineutrophil cytoplasmic antibodies, and circulating immune complexes were also elevated in survivors with hearing loss [56]. Neutralizing antibodies were not detected in primates that succumbed to the infection but developed slowly in survivors approximately 14 dpi [50,56,57]. An early and strong T cell response was noticed in survivors [57]. Viral titers were detected at high levels in the spleen, lung, and liver, and at lower levels in the lymph nodes, kidney, and brain by 7 dpi [38,39,51,56,57,58].
Gross pathologic analysis revealed enlarged livers, spleens, adrenal glands, pancreas and lymph nodes, along with slight lung discoloration and pericardial effusion [38,39,57,58]. Lung samples featured mild to severe interstitial pneumonia with thickening of the alveolar septae [38,57,58]. Interestingly, although Soromba-R infections presented with a significantly less severe disease, the pathology of the lung was remarkable; 50–100% of lobes were reddened with lesions and extensive pulmonary infiltrations [38]. Liver samples were pale yellow and friable, featuring mild and multifocal portal hepatitis with random regions of necrosis [38,50,58]. Brain samples presented with meningoencephalitis in the frontal lobe, brainstem, and cerebellum with lesions. Neuritis was noted in the optic nerve [38,58]. Both lymph nodes and the white pulp of the spleen suffered follicular hyperplasia and mild lymphocytolysis. Spleens were also friable with fibrinous deposits in the red pulp [38,57,58]. Kidney samples appeared congested with mononuclear cell infiltrates [57,58]. Petechial hemorrhage and necrosis were noted on the bladder, while the ovaries and uterus were inflamed [57,58]. The thymus featured marked atrophy; myocarditis and necrotizing coronary arteritis were noted in the heart [58].

6. Surrogate Models of Lassa Fever

6.1. Pichindé Virus in Guinea Pigs

Pichindé virus (PICV) is a non-pathogenic, New World mammarenavirus isolated from cricetine rodents (Oryzomys albigularis) in Colombia, South America [59,60]. PICV infection of Strain 13 guinea pigs can cause Lassa-like disease and therefore has been used as a surrogate LASV model in BSL2 labs (Table 5) [61,62,63]. A minimum of four sequential passages of PICV in guinea pigs was required to result in 100% lethality [63,64]. Infected guinea pigs were hypoactive and lethargic, with ruffled fur, decreased food/water intake, rapid and shallow breathing, slobbering, and significant weight loss before becoming moribund [62,64]. Viremia appeared by 2 dpi and steadily increased until death at 16 dpi [62,63,64]. Infected guinea pigs featured extreme leukopenia beginning approximately 13 dpi and a transient neutrophilia [63]. Serologic findings included impaired platelet function, decreased activity of coagulation factors, and thrombocytopenia, decreased white blood cell concentrations and increased hematocrit [64]. AST concentrations were also elevated, starting from approximately 9 dpi [63]. Histologic analysis indicated pathological lesions in the liver, spleen, pancreas, lungs and gastrointestinal tract [61,62,63,64]. Scattered necrotic regions were found in lymphoid tissue and the bone marrow [64].
Unlike Strain 13 guinea pigs, Hartley outbred guinea pigs did not uniformly succumb to infection by PICV CoAn 4763 strain [63,65]. The lethality was approximately 43% when animals were infected with 3000 PFU PICV CoAn 4763 [63]. Virus was cleared by 16 dpi in survivors [63]. When the CoAn 4763 strain passaged in Strain 13 guinea pigs for 18 passages, the resulting P18 strain was more virulent than the P2 strain, which was passaged only twice [65,66,67]. Infection with 100 PFU of the PICV P18 strain caused weight loss, fever and uniformly lethal infection in outbred guinea pigs [65,66,67]. Virus was present in almost all organs, with the highest titers in the adrenal glands, lungs, stomachs and livers [66]. Lower yet still notable titers were found in the brain [66]. P2-infected guinea pigs did not present with any detectable viral titer in any tested organs [66]. Additionally, P18 PICV-infected guinea pigs presented with a longer and more severe disease than their P2-infected counterparts [66]. The level of viremia was correlated with disease severity [66].

6.2. Pichindé Virus in Golden Hamsters

Pichindé virus infection also caused Lassa-like disease in Golden hamsters (Mesocricetus auratus) with various lethality depending on the virus strains (Table 5) [68]. The lethality could be 100% in new-born LVG/Lak outbred hamsters, and mortality was uncommon after 8 days post-birth. Peak viral titers in adults reached as high as 103 PFU/mL. MHA/Lak inbred hamsters demonstrated 100% lethality with as low as 35 PFU of virus regardless of ages [68]. Adults at 8 dpi developed viral titers over 108 PFU/mL. Both hamster models produced antibodies against the virus. Spleen, liver, and kidneys were the primary affected organs [68].

6.3. Pirital Virus in Golden Hamsters

Pirital virus, a non-human pathogenic New World mammarenavirus isolated from western Venezuela, causes a Lassa-like disease in Golden Hamsters [69]. These hamsters developed a severe disease and died approximately 7 dpi [69]. Interstitial pneumonia, multifocal hepatic necrosis, as well as splenic lymphoid depletion and necrosis were noted upon histologic analysis [69]. The brain, kidneys, and intestine were not significantly affected and there was no significant infiltration of inflammatory cells in the affected tissues [69]. Some of the infected hamsters presented with hemorrhagic signs from the mouth or puncture wounds. The clotting deficiency was noted in the collected blood samples, in which clotting rates were either non-existent or extremely slow [69].

6.4. Lymphocytic Choriomeningitis Virus (LCMV) in Rhesus Monkeys

The virulent WE strain of lymphocytic choriomeningitis virus (LCMV), a pathogenic Old World mammarenavirus, causes a uniformly lethal Lassa-like disease in rhesus monkeys infected intravenously (Table 5) [70]. Viremia was detected beginning at 4 dpi [70]. The liver especially was affected in this model, with significant gene expression changes noted [70,71]. However, of five primates infected intragastrically (IG), lethality only reached 20%, with only two of the monkeys becoming viremic [72]. Signs of disease included weight loss and serological analysis indicated elevated ALT and AST as well as thrombocytopenia, transient neutrophilia [72].

7. Summary

Animal models are essential for pathogenesis studies and LASV vaccine and antiviral developments. An ideal LF animal model should match the disease manifestation and progression, pathological changes, and the various pathogenicity of different strains in humans. Additionally, outbred animals with diverse genetic background have an advantage of mimicking infection in human populations. Other important factors include the immune-competency, the availability and the cost of the animals. The prototypic Josiah strain has been the most commonly used LASV strain in laboratory studies. However, the genetic diversity of LASV should also be considered when developing LF animal models.
The NHP models (Table 4), particularly “crab-eating” (cynomolgus) macaques, develop a disease very similar to clinical cases of LF and thus are excellent models for vaccine and antiviral evaluations as well as pathogenesis studies. However, the use of NHPs is extremely limited due to their relatively high cost, the difficulty of handling the animals, as well as the requirements for experienced staff and adequate space in high containment BSL4 facilities. Additionally, it is not easily feasible to perform NHP studies using large group sizes, making statistical significance difficult to ascertain.
Inbred Strain 13 guinea pigs are useful model animals, but the animals are not readily available and lack genetic diversity. Outbred Hartley guinea pigs are commercially available. However, the widely used Josiah strain must be adapted in guinea pigs in order to cause LF-like disease. PICV infection of Hartley guinea pigs can be used as a surrogate animal model of LF. Using the clinical LASV LF2384 isolate, which was isolated from a fatal case and has experienced minimal passaging in the laboratory, uniformly lethality can be achieved in Hartley guinea pigs without species-specific adaptation. Although further characterization is required, this new model shows much potential as a relevant and relatively inexpensive rodent model that combines the advantages of diverse genetic background, immunocompetency as well as the convenience of the animal’s small size and large numbers that can be used in an experiment, which can ensure the rigor and reproducibility of the studies. However, one limitation of using guinea pigs is the lack of available laboratory reagents and a collection of genetically modified animals for immunological and related studies. Nevertheless, guinea pig models could be ideal for vaccine and antiviral screening and potentially pathogenesis studies. A summary of guinea pig LF disease manifestations and pathologies can be found in Table 3.
Immune-competent laboratory mice are generally resistant to LASV infection (Table 2). The STAT1-/- mouse model is the only known animal model for studying LASV-associated hearing loss. This new mouse model has been used in studies on the pathogenesis and immunology of LF, which indicate an immunopathological mechanism of LF. This mouse model may be useful in initial vaccine and antiviral drug screening, as it is a lethal model of infection. However, its immune-incompetency should be considered, as deficiency in interferon signaling may have negative effects on such studies [73,74].
With the increased fatality of LF in the most recent 2018–2019 outbreaks, there is an urgent need for the rapid development of vaccines and antivirals. Development of small animal models that resemble human disease is crucial to facilitate vaccine and therapeutic testing. The best option at the current stage seems to be performing initial screening in lethal rodent models, such as the aforementioned STAT1-/- mouse model and the newly developed LF2384/outbred Hartley guinea pig model, followed by validation of promising candidates in NHPs. Additionally, the STAT1-/- model is useful as a new platform for investigating the mechanism of LF-associated hearing loss, which affects approximately one third of survivors.

Author Contributions

Review conceptualization and organization were conducted by all authors. The original manuscript was prepared by R.A.S. Manuscript editing was performed by all authors. All authors have read and agree to the published version of the manuscript.

Funding

R.A.S. was supported by the Institute for Translational Sciences at the University of Texas Medical Branch, which is supported in part and by the Clinical and Translational Science Award NRSA (TL1) Training Core (TL1TR001440) from the National Center for Advancing Translational Sciences at the National Institutes of Health. Work in the Paessler laboratory was supported in parts by Public Health Service grants RO1AI093445 and RO1AI129198 and the John. S. Dunn Distinguished Chair in Biodefense endowment. Work in the Ly lab was supported in parts by the Public Health Service grant R01AI131586 and by funds from the USDA National Institute of Food and Agriculture (USDA-NIFA) and from the Minnesota Agricultural Experiment Station. C.H. was supported by UTMB Commitment Fund P84373.

Acknowledgments

We apologize for any works that we were unable to include due to the constraints of the review. The authors would like to thank Junki Maruyama for consultation over the course of writing. C.H. would like to acknowledge the Galveston National Laboratory (supported by the Public Health Service award 5UC7AI094660) for support of his research activity.

Conflicts of Interest

The authors declare no conflict of interest.

References

  1. Günther, S.; Lenz, O. Lassa fever. Br. Med. J. 1972, 4, 253–254. Available online: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1788780/ (accessed on 14 June 2019).
  2. Centers for Disease Control and Prevention. Lassa Fever. 2019. Available online: https://www.cdc.gov/vhf/lassa/index.html (accessed on 15 June 2019).
  3. Frame, J.D.; Baldwin, J.M., Jr.; Gocke, D.J.; Troup, J.M. Lassa fever, a new virus disease of man from West Africa. I. Clinical description and pathological findings. Am. J. Trop. Med. Hyg. 1970, 19, 670–676. [Google Scholar] [CrossRef] [PubMed]
  4. Olayemi, A.; Oyeyiola, A.; Obadare, A.; Igbokwe, J.; Adesina, A.S.; Onwe, F.; Ukwaja, K.N.; Ajayi, N.A.; Rieger, T.; Gunther, S.; et al. Widespread arenavirus occurrence and seroprevalence in small mammals, Nigeria. Parasit Vectors 2018, 11, 416. [Google Scholar] [CrossRef]
  5. Andersen, K.G.; Shapiro, B.J.; Matranga, C.B.; Sealfon, R.; Lin, A.E.; Moses, L.M.; Folarin, O.A.; Goba, A.; Odia, I.; Ehiane, P.E.; et al. Clinical Sequencing Uncovers Origins and Evolution of Lassa Virus. Cell 2015, 162, 738–750. [Google Scholar] [CrossRef] [Green Version]
  6. Manning, J.T.; Forrester, N.; Paessler, S. Lassa virus isolates from Mali and the Ivory Coast represent an emerging fifth lineage. Front. Microbiol. 2015, 6, 1037. [Google Scholar] [CrossRef] [Green Version]
  7. Ehichioya, D.U.; Dellicour, S.; Pahlmann, M.; Rieger, T.; Oestereich, L.; Becker-Ziaja, B.; Cadar, D.; Ighodalo, Y.; Olokor, T.; Omomoh, E.; et al. Phylogeography of Lassa Virus in Nigeria. J. Virol. 2019, 93. [Google Scholar] [CrossRef] [Green Version]
  8. Yun, N.E.; Ronca, S.; Tamura, A.; Koma, T.; Seregin, A.V.; Dineley, K.T.; Miller, M.; Cook, R.; Shimizu, N.; Walker, A.G.; et al. Animal Model of Sensorineural Hearing Loss Associated with Lassa Virus Infection. J. Virol. 2015, 90, 2920–2927. [Google Scholar] [CrossRef] [Green Version]
  9. Welch, S.R.; Scholte, F.E.M.; Albariño, C.G.; Kainulainen, M.H.; Coleman-McCray, J.D.; Guerrero, L.W.; Chakrabarti, A.K.; Klena, J.D.; Nichol, S.T.; Spengler, J.R.; et al. The S Genome Segment Is Sufficient to Maintain Pathogenicity in Intra-Clade Lassa Virus Reassortants in a Guinea Pig Model. Front. Cell. Infect. Microbiol. 2018, 8, 240. [Google Scholar] [CrossRef]
  10. Ibekwe, T.S.; Okokhere, P.O.; Asogun, D.; Blackie, F.F.; Nwegbu, M.M.; Wahab, K.W.; Omilabu, S.A.; Akpede, G.O. Early-onset sensorineural hearing loss in Lassa fever. Eur. Arch. Otorhinolaryngol. 2011, 268, 197–201. [Google Scholar] [CrossRef]
  11. Dan-Nwafor, C.C.; Furuse, Y.; Ilori, E.A.; Ipadeola, O.; Akabike, K.O.; Ahumibe, A.; Ukponu, W.; Bakare, L.; Okwor, T.J.; Joseph, G.; et al. Measures to control protracted large Lassa fever outbreak in Nigeria, 1 January to 28 April 2019. Euro. Surveill. 2019, 24. [Google Scholar] [CrossRef]
  12. World Health Organization. On the Frontlines of the Fight against Lassa Fever in Nigeria. 2018. Available online: http://www.who.int/features/2018/lassa-fever-nigeria/en/ (accessed on 15 June 2019).
  13. Nigeria Centers for Disease Control. 2018 Lassa Fever Outbreak in Nigeria. 2018. Available online: https://ncdc.gov.ng/themes/common/files/sitreps/00235292b8a3f55c01f9ea2eb15c8d3a.pdf (accessed on 15 June 2019).
  14. World Health Organization. Emergencies Preparedness, Response Lassa Fever. 2019. Available online: https://www.who.int/csr/don/archive/disease/lassa_fever/en/ (accessed on 16 June 2019).
  15. McCormick, J.B.; King, I.J.; Webb, P.A.; Scribner, C.L.; Craven, R.B.; Johnson, K.M.; Elliott, L.H.; Belmont-Williams, R. Lassa fever. Effective therapy with ribavirin. N. Engl. J. Med. 1986, 314, 20–26. [Google Scholar] [CrossRef]
  16. Mustapha, A. Lassa fever: Unveiling the misery of the Nigerian health worker. Ann. Nigerian. Med. 2017, 11, 1–5. [Google Scholar]
  17. Walker, D.H.; McCormick, J.B.; Johnson, K.M.; Webb, P.A.; Komba-Kono, G.; Elliott, L.H.; Gardner, J.J. Pathologic and virologic study of fatal Lassa fever in man. Am. J. Pathol. 1982, 107, 349–356. [Google Scholar]
  18. Mateer, E.J.; Huang, C.; Shehu, N.Y.; Paessler, S. Lassa fever-induced sensorineural hearing loss: A neglected public health and social burden. PLoS Negl. Trop. Dis. 2018, 12, e0006187. [Google Scholar] [CrossRef]
  19. Cummins, D.; McCormick, J.B.; Bennett, D.; Samba, J.A.; Farrar, B.; Machin, S.J.; Fisher-Hoch, S.P. Acute sensorineural deafness in Lassa fever. JAMA 1990, 264, 2093–2096. [Google Scholar] [CrossRef]
  20. Price, M.E.; Fisher-Hoch, S.P.; Craven, R.B.; McCormick, J.B. A prospective study of maternal and fetal outcome in acute Lassa fever infection during pregnancy. BMJ 1988, 297, 584–587. [Google Scholar] [CrossRef] [Green Version]
  21. Dunmade, A.D.; Segun-Busari, S.; Olajide, T.G.; Ologe, F.E. Profound bilateral sensorineural hearing loss in nigerian children: Any shift in etiology? J. Deaf Stud. Deaf Educ. 2007, 12, 112–118. [Google Scholar] [CrossRef]
  22. Khan, S.H.; Goba, A.; Chu, M.; Roth, C.; Healing, T.; Marx, A.; Fair, J.; Guttieri, M.C.; Ferro, P.; Imes, T.; et al. New opportunities for field research on the pathogenesis and treatment of Lassa fever. Antiviral. Res. 2008, 78, 103–115. [Google Scholar] [CrossRef]
  23. Johnson, K.M.; McCormick, J.B.; Webb, P.A.; Smith, E.S.; Elliott, L.H.; King, I.J. Clinical virology of Lassa fever in hospitalized patients. J. Infect. Dis. 1987, 155, 456–464. [Google Scholar] [CrossRef]
  24. Winn, W.C., Jr.; Walker, D.H. The pathology of human Lassa fever. Bull. World Health Organ. 1975, 52, 535–545. [Google Scholar]
  25. Walker, D.H.; Wulff, H.; Lange, J.V.; Murphy, F.A. Comparative pathology of Lassa virus infection in monkeys, guinea-pigs, and Mastomys natalensis. Bull. World Health Organ. 1975, 52, 523–534. [Google Scholar] [PubMed]
  26. Granjon, L.; Duplantier, J.-M.; Catalan, J.; Britton-Davidian, J. Systematics of the genus Mastomys (Thomas, 1915) (Rodentia: Muridae): A review. Belg. J. Zool. 1997, 127, 7–18. [Google Scholar]
  27. Rieger, T.; Merkler, D.; Gunther, S. Infection of type I interferon receptor-deficient mice with various old world arenaviruses: A model for studying virulence and host species barriers. PLoS One 2013, 8, e72290. [Google Scholar] [CrossRef]
  28. Yun, N.E.; Seregin, A.V.; Walker, D.H.; Popov, V.L.; Walker, A.G.; Smith, J.N.; Miller, M.; de la Torre, J.C.; Smith, J.K.; Borisevich, V.; et al. Mice lacking functional STAT1 are highly susceptible to lethal infection with Lassa virus. J. Virol. 2013, 87, 10908–10911. [Google Scholar] [CrossRef] [Green Version]
  29. Oestereich, L.; Lüdtke, A.; Ruibal, P.; Pallasch, E.; Kerber, R.; Rieger, T.; Wurr, S.; Bockholt, S.; Pérez-Girón, J.V.; Krasemann, S.; et al. Chimeric Mice with Competent Hematopoietic Immunity Reproduce Key Features of Severe Lassa Fever. PLoS Pathog. 2016, 12, e1005656. [Google Scholar] [CrossRef]
  30. Yun, N.E.; Poussard, A.L.; Seregin, A.V.; Walker, A.G.; Smith, J.K.; Aronson, J.F.; Smith, J.N.; Soong, L.; Paessler, S. Functional interferon system is required for clearance of lassa virus. J. Virol. 2012, 86, 3389–3392. [Google Scholar] [CrossRef] [Green Version]
  31. Oestereich, L.; Rieger, T.; Ludtke, A.; Ruibal, P.; Wurr, S.; Pallasch, E.; Bockholt, S.; Krasemann, S.; Muñoz-Fontela, C.; Gunther, S. Efficacy of Favipiravir Alone and in Combination With Ribavirin in a Lethal, Immunocompetent Mouse Model of Lassa Fever. J. Infect. Dis. 2016, 213, 934–938. [Google Scholar] [CrossRef] [Green Version]
  32. Uckun, F.M.; Petkevich, A.S.; Vassilev, A.O.; Tibbles, H.E.; Titov, L. Stampidine prevents mortality in an experimental mouse model of viral hemorrhagic fever caused by lassa virus. BMC Infect. Dis. 2004, 4, 1. [Google Scholar] [CrossRef] [Green Version]
  33. Flatz, L.; Rieger, T.; Merkler, D.; Bergthaler, A.; Regen, T.; Schedensack, M.; Bestmann, L.; Verschoor, A.; Kreutzfeldt, M.; Bruck, W.; et al. T cell-dependence of Lassa fever pathogenesis. PLoS Pathog. 2010, 6, e1000836. [Google Scholar] [CrossRef] [Green Version]
  34. Jahrling, P.B.; Smith, S.; Hesse, R.A.; Rhoderick, J.B. Pathogenesis of Lassa virus infection in guinea pigs. Infect. Immun. 1982, 37, 771–778. [Google Scholar] [CrossRef] [Green Version]
  35. Bell, T.M.; Shaia, C.I.; Bearss, J.J.; Mattix, M.E.; Koistinen, K.A.; Honnold, S.P.; Zeng, X.; Blancett, C.D.; Donnelly, G.C.; Shamblin, J.D.; et al. Temporal Progression of Lesions in Guinea Pigs Infected With Lassa Virus. Vet. Pathol. 2017, 54, 549–562. [Google Scholar] [CrossRef] [PubMed]
  36. Gary, J.M.; Welch, S.R.; Ritter, J.M.; Coleman-McCray, J.; Huynh, T.; Kainulainen, M.H.; Bollweg, B.C.; Parihar, V.; Nichol, S.T.; Zaki, S.R.; et al. Lassa Virus Targeting of Anterior Uvea and Endothelium of Cornea and Conjunctiva in Eye of Guinea Pig Model. Emerg. Infect. Dis. 2019, 25, 865–874. [Google Scholar] [CrossRef] [PubMed]
  37. Cashman, K.A.; Smith, M.A.; Twenhafel, N.A.; Larson, R.A.; Jones, K.F.; Allen, R.D., 3rd; Dai, D.; Chinsangaram, J.; Bolken, T.C.; Hruby, D.E.; et al. Evaluation of Lassa antiviral compound ST-193 in a guinea pig model. Antiviral. Res. 2011, 90, 70–79. [Google Scholar] [CrossRef] [PubMed]
  38. Safronetz, D.; Mire, C.; Rosenke, K.; Feldmann, F.; Haddock, E.; Geisbert, T.; Feldmann, H. A recombinant vesicular stomatitis virus-based Lassa fever vaccine protects guinea pigs and macaques against challenge with geographically and genetically distinct Lassa viruses. PLoS Negl. Trop. Dis. 2015, 9, e0003736. [Google Scholar] [CrossRef] [PubMed]
  39. Safronetz, D.; Strong, J.E.; Feldmann, F.; Haddock, E.; Sogoba, N.; Brining, D.; Geisbert, T.W.; Scott, D.P.; Feldmann, H. A recently isolated Lassa virus from Mali demonstrates atypical clinical disease manifestations and decreased virulence in cynomolgus macaques. J. Infect. Dis. 2013, 207, 1316–1327. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  40. Cross, R.W.; Mire, C.E.; Branco, L.M.; Geisbert, J.B.; Rowland, M.M.; Heinrich, M.L.; Goba, A.; Momoh, M.; Grant, D.S.; Fullah, M.; et al. Treatment of Lassa virus infection in outbred guinea pigs with first-in-class human monoclonal antibodies. Antiviral. Res. 2016, 133, 218–222. [Google Scholar] [CrossRef] [Green Version]
  41. Safronetz, D.; Rosenke, K.; Westover, J.B.; Martellaro, C.; Okumura, A.; Furuta, Y.; Geisbert, J.; Saturday, G.; Komeno, T.; Geisbert, T.W.; et al. The broad-spectrum antiviral favipiravir protects guinea pigs from lethal Lassa virus infection post-disease onset. Sci. Rep. 2015, 5, 14775. [Google Scholar] [CrossRef]
  42. Stein, D.R.; Warner, B.M.; Soule, G.; Tierney, K.; Frost, K.L.; Booth, S.; Safronetz, D. A recombinant vesicular stomatitis-based Lassa fever vaccine elicits rapid and long-term protection from lethal Lassa virus infection in guinea pigs. NPJ Vaccines 2019, 4, 8. [Google Scholar] [CrossRef]
  43. Maruyama, J.; Mateer, E.J.; Manning, J.T.; Sattler, R.; Seregin, A.V.; Bukreyeva, N.; Jones, F.R.; Balint, J.P.; Gabitzsch, E.S.; Huang, C.; et al. Adenoviral vector-based vaccine is fully protective against lethal Lassa fever challenge in Hartley guinea pigs. Vaccine 2019, 37, 6824–6831. [Google Scholar] [CrossRef]
  44. Walker, D.H.; Johnson, K.M.; Lange, J.V.; Gardner, J.J.; Kiley, M.P.; McCormick, J.B. Experimental infection of rhesus monkeys with Lassa virus and a closely related arenavirus, Mozambique virus. J. Infect. Dis. 1982, 146, 360–368. [Google Scholar] [CrossRef] [PubMed]
  45. Maruyama, J.; Manning, J.T.; Mateer, E.J.; Sattler, R.; Bukreyeva, N.; Huang, C.; Paessler, S. Lethal Infection of Lassa Virus Isolated from a Human Clinical Sample in Outbred Guinea Pigs without Adaptation. mSphere 2019, 4. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  46. Walker, D.H.; Wulff, H.; Murphy, F.A. Experimental Lassa virus infection in the squirrel monkey. Am. J. Pathol. 1975, 80, 261–278. [Google Scholar] [PubMed]
  47. Carrion, R., Jr.; Brasky, K.; Mansfield, K.; Johnson, C.; Gonzales, M.; Ticer, A.; Lukashevich, I.; Tardif, S.; Patterson, J. Lassa virus infection in experimentally infected marmosets: Liver pathology and immunophenotypic alterations in target tissues. J. Virol. 2007, 81, 6482–6490. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  48. Callis, R.T.; Jahrling, P.B.; DePaoli, A. Pathology of Lassa virus infection in the rhesus monkey. Am. J. Trop. Med. Hyg. 1982, 31, 1038–1045. [Google Scholar] [CrossRef] [PubMed]
  49. Jahrling, P.B.; Hesse, R.A.; Eddy, G.A.; Johnson, K.M.; Callis, R.T.; Stephen, E.L. Lassa virus infection of rhesus monkeys: Pathogenesis and treatment with ribavirin. J. Infect. Dis. 1980, 141, 580–589. [Google Scholar] [CrossRef]
  50. Cashman, K.A.; Wilkinson, E.R.; Shaia, C.I.; Facemire, P.R.; Bell, T.M.; Bearss, J.J.; Shamblin, J.D.; Wollen, S.E.; Broderick, K.E.; Sardesai, N.Y.; et al. A DNA vaccine delivered by dermal electroporation fully protects cynomolgus macaques against Lassa fever. Hum. Vaccin. Immunother. 2017, 13, 2902–2911. [Google Scholar] [CrossRef]
  51. Geisbert, T.W.; Jones, S.; Fritz, E.A.; Shurtleff, A.C.; Geisbert, J.B.; Liebscher, R.; Grolla, A.; Ströher, U.; Fernando, L.; Daddario, K.M.; et al. Development of a new vaccine for the prevention of Lassa fever. PLoS Med. 2005, 2, e183. [Google Scholar] [CrossRef]
  52. Jiang, J.; Banglore, P.; Cashman, K.A.; Schmaljohn, C.S.; Schultheis, K.; Pugh, H.; Nguyen, J.; Humeau, L.M.; Broderick, K.E.; Ramos, S.J. Immunogenicity of a protective intradermal DNA vaccine against lassa virus in cynomolgus macaques. Hum. Vaccin. Immunother. 2019, 15, 2066–2074. [Google Scholar] [CrossRef] [Green Version]
  53. Mire, C.E.; Cross, R.W.; Geisbert, J.B.; Borisevich, V.; Agans, K.N.; Deer, D.J.; Heinrich, M.L.; Rowland, M.M.; Goba, A.; Momoh, M.; et al. Human-monoclonal-antibody therapy protects nonhuman primates against advanced Lassa fever. Nat. Med. 2017, 23, 1146–1149. [Google Scholar] [CrossRef] [Green Version]
  54. Fisher-Hoch, S.P.; Mitchell, S.W.; Sasso, D.R.; Lange, J.V.; Ramsey, R.; McCormick, J.B. Physiological and immunologic disturbances associated with shock in a primate model of Lassa fever. J. Infect. Dis. 1987, 155, 465–474. [Google Scholar] [CrossRef]
  55. Lange, J.V.; Mitchell, S.W.; McCormick, J.B.; Walker, D.H.; Evatt, B.L.; Ramsey, R.R. Kinetic study of platelets and fibrinogen in Lassa virus-infected monkeys and early pathologic events in Mopeia virus-infected monkeys. Am. J. Trop. Med. Hyg. 1985, 34, 999–1007. [Google Scholar] [CrossRef] [PubMed]
  56. Cashman, K.A.; Wilkinson, E.R.; Zeng, X.; Cardile, A.P.; Facemire, P.R.; Bell, T.M.; Bearss, J.J.; Shaia, C.I.; Schmaljohn, C.S. Immune-Mediated Systemic Vasculitis as the Proposed Cause of Sudden-Onset Sensorineural Hearing Loss following Lassa Virus Exposure in Cynomolgus Macaques. mBio 2018, 9. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  57. Baize, S.; Marianneau, P.; Loth, P.; Reynard, S.; Journeaux, A.; Chevallier, M.; Tordo, N.; Deubel, V.; Contamin, H. Early and strong immune responses are associated with control of viral replication and recovery in lassa virus-infected cynomolgus monkeys. J. Virol. 2009, 83, 5890–5903. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  58. Hensley, L.E.; Smith, M.A.; Geisbert, J.B.; Fritz, E.A.; Daddario-DiCaprio, K.M.; Larsen, T.; Geisbert, T.W. Pathogenesis of Lassa fever in cynomolgus macaques. Virol. J. 2011, 8, 205. [Google Scholar] [CrossRef] [Green Version]
  59. Buchmeier, M.; Adam, E.; Rawls, W.E. Serological evidence of infection by Pichindé virus among laboratory workers. Infect. Immun. 1974, 9, 821–823. [Google Scholar] [CrossRef] [Green Version]
  60. Trapido, H.; Sanmartin, C. Pichindé virus, a new virus of the Tacaribe group from Colombia. Am. J. Trop. Med. Hyg. 1971, 20, 631–641. [Google Scholar] [CrossRef]
  61. Aronson, J.F.; Herzog, N.K.; Jerrells, T.R. Pathological and virological features of arenavirus disease in guinea pigs. Comparison of two Pichindé virus strains. Am. J. Pathol. 1994, 145, 228–235. [Google Scholar]
  62. Connolly, B.M.; Jenson, A.B.; Peters, C.J.; Geyer, S.J.; Barth, J.F.; McPherson, R.A. Pathogenesis of Pichindé virus infection in strain 13 guinea pigs: An immunocytochemical, virologic, and clinical chemistry study. Am. J. Trop. Med. Hyg. 1993, 49, 10–24. [Google Scholar] [CrossRef]
  63. Jahrling, P.B.; Hesse, R.A.; Rhoderick, J.B.; Elwell, M.A.; Moe, J.B. Pathogenesis of a pichindé virus strain adapted to produce lethal infections in guinea pigs. Infect. Immun. 1981, 32, 872–880. [Google Scholar] [CrossRef] [Green Version]
  64. Cosgriff, T.M.; Jahrling, P.B.; Chen, J.P.; Hodgson, L.A.; Lewis, R.M.; Green, D.E.; Smith, J.I. Studies of the coagulation system in arenaviral hemorrhagic fever: Experimental infection of strain 13 guinea pigs with Pichindé virus. Am. J. Trop. Med. Hyg. 1987, 36, 416–423. [Google Scholar] [CrossRef]
  65. Zhang, L.; Marriott, K.; Aronson, J.F. Sequence analysis of the small RNA segment of guinea pig-passaged Pichindé virus variants. Am. J. Trop. Med. Hyg. 1999, 61, 220–225. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  66. Lan, S.; McLay Schelde, L.; Wang, J.; Kumar, N.; Ly, H.; Liang, Y. Development of infectious clones for virulent and avirulent pichindé viruses: A model virus to study arenavirus-induced hemorrhagic fevers. J. Virol. 2009, 83, 6357–6362. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  67. Zhang, L.; Marriott, K.A.; Harnish, D.G.; Aronson, J.F. Reassortant analysis of guinea pig virulence of pichindé virus variants. Virology 2001, 290, 30–38. [Google Scholar] [CrossRef] [Green Version]
  68. Buchmeier, M.J.; Rawls, W.E. Variation between strains of hamsters in the lethality of Pichindé virus infections. Infect. Immun. 1977, 16, 413–421. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  69. Xiao, S.Y.; Zhang, H.; Yang, Y.; Tesh, R.B. Pirital virus (Arenaviridae) infection in the syrian golden hamster, Mesocricetus auratus: A new animal model for arenaviral hemorrhagic fever. Am. J. Trop. Med. Hyg. 2001, 64, 111–118. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  70. Djavani, M.M.; Crasta, O.R.; Zapata, J.C.; Fei, Z.; Folkerts, O.; Sobral, B.; Swindells, M.; Bryant, J.; Davis, H.; Pauza, C.D.; et al. Early blood profiles of virus infection in a monkey model for Lassa fever. J. Virol. 2007, 81, 7960–7973. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  71. Djavani, M.; Crasta, O.R.; Zhang, Y.; Zapata, J.C.; Sobral, B.; Lechner, M.G.; Bryant, J.; Davis, H.; Salvato, M.S. Gene expression in primate liver during viral hemorrhagic fever. Virol. J. 2009, 6, 20. [Google Scholar] [CrossRef] [Green Version]
  72. Rodas, J.D.; Lukashevich, I.S.; Zapata, J.C.; Cairo, C.; Tikhonov, I.; Djavani, M.; Pauza, C.D.; Salvato, M.S. Mucosal arenavirus infection of primates can protect them from lethal hemorrhagic fever. J. Med. Virol. 2004, 72, 424–435. [Google Scholar] [CrossRef] [Green Version]
  73. Clarke, E.C.; Bradfute, S.B. The use of mice lacking type I or both type I and type II interferon responses in research on hemorrhagic fever viruses. Part 1: Potential effects on adaptive immunity and response to vaccination. Antiviral. Res. 2020, 174, 104703. [Google Scholar] [CrossRef] [PubMed]
  74. Zivcec, M.; Spiropoulou, C.F.; Spengler, J.R. The use of mice lacking type I or both type I and type II interferon responses in research on hemorrhagic fever viruses. Part 2: Vaccine efficacy studies. Antiviral. Res. 2020, 174, 104702. [Google Scholar] [CrossRef]
Table
Table 1. Information for Lassa virus (LASV) strains examined in animal models *.
Table 1. Information for Lassa virus (LASV) strains examined in animal models *.
StrainLineageLethal/FatalHostIsolation CountryIsolation YearReference
JosiahIVYesHumanSierra Leone1976[6]
AV VYesHumanGhana/Ivory Coast2000[6]
Ba366 IVNoMastomysnatalensisGuinea2003[6]
LF2384IVYesHumanSierra Leone2012[6,8]
LF2450IVNoHumanSierra Leone2012[6,8]
Soromba-RVNoMastomysnatalensisSoromba, Mali2009[6]
PinneoINoHumanLassa, Nigeria1969[6]
NJ2015IVYesHumanLiberia2015[9]
* Only strains mentioned in this review that have known isolation information are listed in this table.
Table
Table 2. Mouse models of LASV infection.
Table 2. Mouse models of LASV infection.
MouseVirus StrainMax. DoseRouteLethalitySigns of DiseaseAffected OrgansReference
Natal mastomysUnknownNot providedIP dNoasymptomatic, persistent infection, virus shed in saliva and urinelung, spleen, liver, kidney, brain, bladder, lymph nodes[25]
IFNAR-/- Josiah, AV, BA366, Nig04-10105 PFUIV eNopersistent viremia, bodyweight loss, no fever and neurological signslung, liver, spleen brain, kidney, heart[27,28,29,30]
Chimeric IFNAR-/-B6Ba366, AV, Ba289, Nig04-10, Nig-CSF103 FFUIP100%liver damage, vascular leakage, systemic viral dissemination, weight loss, hypothermia, elevated AST/ALT ratioliver, lung, spleen, kidney, heart, brain[29,31]
IFNαβ/γR-/-Josiah, LF2384 a LF2450 b105 PFUIPNominor and transient weight loss, clearance of virus by 25 dpi, no hearing lossspleen, lung, liver, brain, kidney[8,30]
STAT1-/-Josiah104 PFUIP100%weight loss, systematic infectionspleen, lung, liver, brain, kidney[28]
LF2384 a
(fatal)		105 PFUIP80%fever, high level viremia, weight loss, increased ALT level, decreased albumin, WBC, and monocyte counts, hearing loss associated with infiltration of CD3+ lymphocytesbrain, liver, spleen, lung, kidney, heart[8,28]
LF2450 b
(non-fatal)		105 PFUIP0–50%hearing lossbrain, liver, spleen, lung, kidney, heart[8]
CBAJosiah103 PFUIC f70–100%scruffy fur, seizures, weight loss, immobility, and severe decubitus paralysisnot stated[32]
HHDBa366 C106 PFUIV22%ruffled fur, lethargy, elevated AST level, high level viremia, severe pneumonitisliver, lung, spleen, kidney[33]
Note: a LF2384: clinical isolate from a lethally infected patient; b LF2450: clinical isolate from a survivor; C isolate from Natal mastomys; PFU, plaque forming unit; d IP: intraperitoneal; e IV: intravenous; f IC: intracranial.
Table
Table 3. Guinea pig models of LASV infection.
Table 3. Guinea pig models of LASV infection.
Guinea PigStrainMax. DoseRouteLethalitySigns of DiseaseAffected OrgansRefences
Strain 13
(inbred)		Josiah> 2 PFU104 TCID50SC c
IP		>90%weight loss, fever, ruffled fur, hunched posture, conjunctivitis, hepatitis, interstitial pneumonia, edema and hemorrhage in lungslung, spleen, pancreas, lymph nodes, adrenal and salivary glands, kidneys, liver, heart[34,36,37]
Z-132104 TCID50IP100%Josiah-like lung, liver, spleen[38,39]
Soromba-R104 TCID50IP0–57%survivors only show minor weight lossliver, lung, spleen[28,34,35,38,39]
Pinneo104 TCID50IPNomild to moderate disease N.A. *[38]
NJ2015104 FFUSCNoweight loss, fever, red and swollen conjunctivaeye (focus of the study)[36]
Hartley
(outbred)		Josiah>2 PFU103 PFUSCIP30–67%inapparent infection in survivorsN.A. *[25,34,35,40,41]
GPA-Josiah a103 TCID50IP100%weight loss, fever, lethargy, respiratory distress, hypothermiaspleen, liver, lung[25,34,35,40,41,42]
LF2384 b104 PFUIP100%fever, weight loss, hypothermia, lethargy, thrombocytopenia, neutropenia, and lymphopenialiver, kidney, spleen, lung, brain[43]
* N.A: not available; a GPA-Josiah: guinea pig-adapted LASV Josiah strain; b LF2384: clinical isolate from a fatally infected LF patient; c SC: subcutaneous
Table
Table 4. Non-human primate (NHP) models of LASV infection a.
Table 4. Non-human primate (NHP) models of LASV infection a.
NHPLASV StrainMax. DoseRouteLethalitySigns of DiseaseAffected OrgansReference
squirrel monkeysBah106.8 TCID50IM b25%depression, tremors, drooling, anorexia, lassitude, polydipsialiver, kidney, lymph nodes, spleen, brain, adrenal gland, heart[46]
marmosetJosiah106 PFUSC100%low fever, rapid weight loss, depression, anorexia, elevated concentrations of AST, ALT, alkaline phosphatase, decreased concentrations of albumin and plateletliver, spleen, lymph nodes, kidney, lung, adrenal gland[47]
rhesus monkeyJosiah106.1 PFUSC50–60%severe petechial rash, hiccups, lethargy, aphagia, huddled posture, constipation, conjunctivitis, anorexia, weight loss, decreased water intake/dehydration, facial and periorbital edema, bleeding from the gums and nares, cough, feveradrenal glands, liver, lung, pancreas, brain, bone marrow, kidney, lymph nodes, spleen, muscle, heart, thymus, testis, salivary gland, CSF, intestines[44,48,49]
“crab-eating” cynomolgus macaquesJosiah104 PFUIMUp to 100%fever, weight loss, lethargy, dull appearance, reluctance to move/hypoactivity, anorexia, rashes, facial edema, hunched posture, ruffled fur, piloerection, bleeding from puncture sites, dehydration, epistaxis, acute respiratory syndrome, neurological signs including deafnesslymph nodes, spleen, liver, reproductive organs, kidney, lung, heart, CNS[38,39,50,51,52,53]
Z-132104 TCID50IM100%Josiah-likespleen, liver, lung[38,39]
Soromba-R104 TCID50IM66%less severe than Josiah strain infection, moderate to severe pulmonary lesionssimilar to Josiah and Z-132[39]
a Another NHP model, for which the literature was not available to the authors, is the hydramas baboon model; b IM: intramuscular.
Table
Table 5. Surrogate models of LASV infection.
Table 5. Surrogate models of LASV infection.
AnimalVirus/StrainMax. DoseRouteLethalitySigns of DiseaseAffected OrgansReference
Strain 13
(inbred) guinea pig		Pichindé virus>3 PFUSC100%hypoactivity, lethargy, ruffled fur, decreased appetite, rapid/shallow breathing, slobbering, weight loss, leukopenia, and transient neutrophilialiver, spleen, pancreas, lung, gastrointestinal tract, lymphoid tissue, bone marrow[61,62,63,64]
Hartley
(outbred) guinea pig		Pichindé virus/P18100 PFUIP100%weight loss and feveradrenal glands, lung, stomach, liver, brain, heart, spleen, pancreas, intestine, kidney, lymph node[65,67]
Pichindé virus/P2104 PFUIP<100%avirulentnone[66]
Pichindé virus/CoAn 47833000 PFUIP43%weight loss and fevercleared in survivors[65]
LVG/Lak outbred golden hamstersPichindé virus500 PFUSC0–100%lethal infection up to 8 days post-birth; uncommon afterwardsspleen, liver, kidney[68]
MHA/Lak inbred golden hamstersPichindé virus3.5 × 106 PFUIP100%lethal infection regardless of agespleen, liver, kidney[68]
Golden hamstersPirital virus105 TCID50IP>50%hemorrhage, interstitial pneumonia, multifocal hepatic necrosis, splenic lymphoid depletion and necrosislung, liver, spleen[69]
Rhesus monkeysLCMV-WE103 PFUIV100%not listednot listed[70,71]
108 PFUIG a20%weight loss, elevated AST and ALT, thrombocytopenia, transient neutrophilialiver[72]
a IG: intragastic

Share and Cite

MDPI and ACS Style

Sattler, R.A.; Paessler, S.; Ly, H.; Huang, C. Animal Models of Lassa Fever. Pathogens 2020, 9, 197. https://doi.org/10.3390/pathogens9030197

AMA Style

Sattler RA, Paessler S, Ly H, Huang C. Animal Models of Lassa Fever. Pathogens. 2020; 9(3):197. https://doi.org/10.3390/pathogens9030197

Chicago/Turabian Style

Sattler, Rachel A., Slobodan Paessler, Hinh Ly, and Cheng Huang. 2020. "Animal Models of Lassa Fever" Pathogens 9, no. 3: 197. https://doi.org/10.3390/pathogens9030197

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop